Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06422871 · ClinicalTrials.gov registry record

PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

A clinical trial of End Stage Renal Disease and Hemodialysis Access Failure, sponsored by Merit Medical Systems.

Recruiting
Registry status
100
Enrollment target
3
Study locations

NCT06422871: Recruiting study of End Stage Renal Disease and Hemodialysis Access Failure, sponsored by Merit Medical Systems.

NCT06422871 is a study of End Stage Renal Disease and Hemodialysis Access Failure that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 100 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06422871, a study of End Stage Renal Disease and Hemodialysis Access Failure, is actively recruiting participants, sponsored by Merit Medical Systems.

RECRUITING
Registry status
100 participants
Enrollment target
3
Study locations

Study Summary

The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit during the 4 visit timepoints over 2 years, the participant will be followed by phone to check their current health and dialysis status.

Primary Outcome

Clinical Success, defined as maintenance of access circuit patency in the absence of device-related infection or bacteremia

Interventions

  • DEVICE HeRO® Graft System or Super HeRO® System

Study Locations (3)

Florida

  • Sarasota Memorial Health Care System - Sarasota

North Carolina

  • WakeMed - Raleigh

Texas

  • Baylor Scott & White Heart and Vascular Hospital - Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-07-28
Est. Completion 2028-12-28
Merit Medical Systems

18 total trials

What NCT06422871 shows while recruiting

NCT06422871 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which HeRO® Graft System or Super HeRO® System is the first listed.

NCT06422871 reports a single indexed study location in Florida, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT06422871 about?

NCT06422871 is a clinical study titled "PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis". The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of ...

What is the current status of trial NCT06422871?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-07-28. Estimated completion is 2028-12-28.

What conditions does trial NCT06422871 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Hemodialysis Access Failure.

What interventions are being tested in trial NCT06422871?

The interventions under investigation include: HeRO® Graft System or Super HeRO® System (DEVICE).

Who is sponsoring clinical trial NCT06422871?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06422871 being conducted?

This trial has 3 study locations across Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06422871's enrollment target sits among peer trials

100 34th of 86 higher than 50 of 86 other End Stage Renal Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06422871, the US trial registry maintained by the National Library of Medicine. NCT06422871 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.